Ngā hua rapu - Heinz Wiendl

Whakamahine hua
  1. 1
    CD8<sup>+</sup>T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability

    CD8<sup>+</sup>T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability mā Nico Melzer, Sven G. Meuth, Heinz Wiendl

    I whakaputaina 2009
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system

    Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system mā Nico Melzer, Sven G. Meuth, Heinz Wiendl

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis

    Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis mā Nicholas Schwab, Tilman Schneider‐Hohendorf, Heinz Wiendl

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    TRPM2 Cation Channels Modulate T Cell Effector Functions and Contribute to Autoimmune CNS Inflammation

    TRPM2 Cation Channels Modulate T Cell Effector Functions and Contribute to Autoimmune CNS Inflammation mā Nico Melzer, Gordon Hicking, Kerstin Göbel, Heinz Wiendl

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

    Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond mā Tobias Ruck, Stefan Bittner, Heinz Wiendl, Sven G. Meuth

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Neurons as targets for T cells in the nervous system

    Neurons as targets for T cells in the nervous system mā Roland Liblau, Daniel Gonzalez‐Dunia, Heinz Wiendl, Frauke Zipp

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    From the Background to the Spotlight: TASK Channels in Pathological Conditions

    From the Background to the Spotlight: TASK Channels in Pathological Conditions mā Stefan Bittner, Thomas Budde, Heinz Wiendl, Sven G. Meuth

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Gut–CNS-Axis as Possibility to Modulate Inflammatory Disease Activity—Implications for Multiple Sclerosis

    Gut–CNS-Axis as Possibility to Modulate Inflammatory Disease Activity—Implications for Multiple Sclerosis mā Ann-Katrin Fleck, Detlef Schuppan, Heinz Wiendl, Luisa Klotz

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature

    Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature mā Catharina Korsukewitz, Stephen W. Reddel, Amit Bar‐Or, Heinz Wiendl

    I whakaputaina 2020
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Bruton tyrosine kinase inhibitors for multiple sclerosis

    Bruton tyrosine kinase inhibitors for multiple sclerosis mā Julia Krämer, Amit Bar‐Or, Timothy J. Turner, Heinz Wiendl

    I whakaputaina 2023
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    IL-17 Silencing Does Not Protect Nonobese Diabetic Mice from Autoimmune Diabetes

    IL-17 Silencing Does Not Protect Nonobese Diabetic Mice from Autoimmune Diabetes mā Julie Joseph, Stefan Bittner, Fabian Kaiser, Heinz Wiendl, Stephan Kissler

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Myelin Oligodendrocyte Glycoprotein (MOG&lt;sub&gt;35-55&lt;/sub&gt;) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice

    Myelin Oligodendrocyte Glycoprotein (MOG&lt;sub&gt;35-55&lt;/sub&gt;) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice mā Stefan Bittner, Ali Maisam Afzali, Heinz Wiendl, Sven G. Meuth

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Can cognitive assessment really discriminate early stages of Alzheimer’s and behavioural variant frontotemporal dementia at initial clinical presentation?

    Can cognitive assessment really discriminate early stages of Alzheimer’s and behavioural variant frontotemporal dementia at initial clinical presentation? mā Sophia Reul, Hubertus Lohmann, Heinz Wiendl, Thomas Duning, Andreas Johnen

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Generating microglia from human pluripotent stem cells: novel in vitro models for the study of neurodegeneration

    Generating microglia from human pluripotent stem cells: novel in vitro models for the study of neurodegeneration mā Anna M. Speicher, Heinz Wiendl, Sven G. Meuth, Matthias Pawlowski

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Targeting B cells in relapsing–remitting multiple sclerosis: from pathophysiology to optimal clinical management

    Targeting B cells in relapsing–remitting multiple sclerosis: from pathophysiology to optimal clinical management mā Stefan Bittner, Tobias Ruck, Heinz Wiendl, Oliver Grauer, Sven G. Meuth

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Teriflunomide and Its Mechanism of Action in Multiple Sclerosis

    Teriflunomide and Its Mechanism of Action in Multiple Sclerosis mā Amit Bar‐Or, Andrew R. Pachner, Françoise Menguy-Vacheron, Johanne Kaplan, Heinz Wiendl

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients

    Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients mā Ute Feger, Claudia Luther, Simone Poeschel, Arthur Melms, Eva Tolosa, Heinz Wiendl

    I whakaputaina 2007
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    The role of dendritic cells in CNS autoimmunity

    The role of dendritic cells in CNS autoimmunity mā Alla L. Zozulya, Benjamin D. Clarkson, Sonja Ortler, Zsuzsanna Fábry, Heinz Wiendl

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis

    Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis mā Gıancarlo Comı, Hans‐Peter Hartung, Rajesh Bakshi, Ian M. Williams, Heinz Wiendl

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Neonatal Fc Receptor–Targeted Therapies in Neurology

    Neonatal Fc Receptor–Targeted Therapies in Neurology mā Christopher Nelke, Marianna Spatola, Christina B. Schroeter, Heinz Wiendl, Jan D. Lünemann

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: